Efficacy of cumulative doses of salbutamol administered via Turbuhaler® or Diskhaler® in patients with reversible airway obstruction

被引:8
作者
Carlsson, LG [1 ]
Arwestrom, E
Friberg, K
Kallen, A
Lunde, H
Lofdahl, CG
机构
[1] Uddevalla Cent Hosp, Dept Med, S-45180 Uddevalla, Sweden
[2] Draco Lakemedel AB, Lund, Sweden
[3] Astro Draco AB, Lund, Sweden
[4] Univ Gothenburg, Sahlgrens Univ Hosp, Div Pulm Med, Gothenburg, Sweden
[5] Univ Gothenburg, Sahlgrens Univ Hosp, Div Clin Pharmacol, Gothenburg, Sweden
[6] Univ Lund Hosp, Dept Resp Med, S-22185 Lund, Sweden
关键词
Diskhaler (R); efficacy; relative potency; salbutamol; Turbuhaler (R);
D O I
10.1111/j.1398-9995.1998.tb03959.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
The study aimed to estimate the relative dose potency of salbutamol inhaled via Turbuhaler(R) and Diskhaler(R). The 24 adult patients participating had chronic reversible airway obstruction. The study was of a double-blind, double-dummy, crossover, randomized design. Five doses of salbutamol Turbuhaler, 50, 50, 100, 200, and 400 mu g, were given on one study day at intervals of 30 min. On another study day, five doses of salbutamol Diskhaler? 200, 200, 400, 800, and 1600 mu g, were given with the same interval. The treatment days were separated by a washout period of at least 24 h. The inhalation technique was standardized and supervised. Efficacy variables were recorded before and after each study dose. The primary efficacy variable was forced expiratory volume in Is (FEV1). When parallel and linear cumulative dose-response curves were statistically compared on a logarithmic scale, the dose potency of salbutamol Turbuhaler vs salbutamol Diskhaler was 1.99 (95% confidence interval 1.52-2.54). This study indicates that only half the dose of salbutamol is required via Turbuhaler as via Diskhaler for the same bronchodilating effect.
引用
收藏
页码:712 / 715
页数:4
相关论文
共 16 条
[1]  
[Anonymous], 1987, AM REV RESPIR DIS, V136, P225
[2]   The inhalation device influences lung deposition and bronchodilating effect of terbutaline [J].
Borgstrom, L ;
Derom, E ;
Stahl, E ;
WahlinBoll, E ;
Pauwels, R .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (05) :1636-1640
[3]   TOTAL AND REGIONAL LUNG DEPOSITION OF TERBUTALINE SULFATE INHALED VIA A PRESSURIZED MDI OR VIA TURBUHALER (R) [J].
BORGSTROM, L ;
NEWMAN, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1993, 97 (1-3) :47-53
[4]  
BORGSTROM L, 1993, THESIS UPPSALA U, V105
[5]   COMPARISON OF CUMULATIVE AND NON-CUMULATIVE TECHNIQUES TO MEASURE DOSE-RESPONSE CURVES FOR BETA-AGONISTS IN PATIENTS WITH ASTHMA [J].
BRITTON, J ;
TATTERSFIELD, A .
THORAX, 1984, 39 (08) :597-599
[6]   CLINICAL COMPARISON OF INHALED BUDESONIDE DELIVERED EITHER VIA PRESSURIZED METERED DOSE INHALER OR TURBUHALER [J].
ENGEL, T ;
HEINIG, JH ;
MALLING, HJ ;
SCHARLING, B ;
NIKANDER, K ;
MADSEN, F .
ALLERGY, 1989, 44 (03) :220-225
[7]   BRONCHODILATOR EFFECTS OF DRY SALBUTAMOL POWDER ADMINISTERED BY ROTAHALER [J].
HARTLEY, JPR ;
NOGRADY, SG ;
GIBBY, OM ;
SEATON, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 4 (06) :673-675
[8]   TERBUTALINE VIA PRESSURIZED METERED-DOSE INHALED (P-MDI) AND TURBUHALER(R) IN HIGHLY REACTIVE ASTHMATIC-PATIENTS [J].
JACKSON, L ;
STAHL, E ;
HOLGATE, ST .
EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (09) :1598-1601
[9]   Differences in bronchodilating potency of salbutamol in Turbuhaler® as compared with a pressurized metered-dose inhaler formulation in patients with reversible airway obstruction [J].
Lofdahl, CG ;
Andersson, L ;
Bondesson, E ;
Carlsson, LG ;
Friberg, K ;
Hedner, J ;
Hornblad, Y ;
Jemsby, P ;
Kallen, A ;
Ullman, A ;
Werner, S ;
Svedmyr, N .
EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (11) :2474-2478
[10]  
LOFDAHL CG, 1994, ALLERGY CLIN IMMU S2, V6, P383